<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833920</url>
  </required_header>
  <id_info>
    <org_study_id>539</org_study_id>
    <nct_id>NCT04833920</nct_id>
  </id_info>
  <brief_title>Effect tDCS of Motor Cortex on Chemotherapy Induced Peripheral Neuropathy</brief_title>
  <official_title>Effect of Motor Cortex Stimulation by Concentric Electrode Transcranial Direct Current Stimulation on Chemotherapy Induced Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of&#xD;
      anticancer medication such as vinca alkaloids (including vincristine), taxanes (including&#xD;
      paclitaxel), and platinum preparations (including cisplatin and oxaliplatin)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of&#xD;
      anticancer medication such as vinca alkaloids (including vincristine), taxanes (including&#xD;
      paclitaxel), and platinum preparations (including cisplatin and oxaliplatin) . CIPN is one of&#xD;
      several long term side effects of anticancer medications that can appear during and after&#xD;
      treatment. CIPN symptoms include pain, dysesthesia, motor and sensory disorders. CIPN can&#xD;
      also be insufficiently responsive to pharmaceutical therapy similar to other types of&#xD;
      refractory neuropathic pain This study is designed to evaluate the effect of two concentric&#xD;
      electrode transcranial direct current stimulation (CE-tDCS) over the primary motor cortex (M)&#xD;
      in management of chemotherapy induced peripheral neuropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the visual analogue scale</measure>
    <time_frame>0 (prestimulation), on the 5th day, 15th days and one month after the last session</time_frame>
    <description>patient describe his pain scored from 0 to 10 where 0=no pain and 10=the worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in the Leeds Assessment of neuropathic Symptoms and signs (LANSS)</measure>
    <time_frame>0 (prestimulation),on the 5th day, 15th days and one month after the last session</time_frame>
    <description>the patients will be asked to describe his pain by answering questions in yes or no; score ≥ 12 suggests neuropathic pain is likely to be involved and score &lt; 12 suggests that neuropathic pain is unlikely to be involved</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>active tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tDCS targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial dirrect current brain stimuation</intervention_name>
    <description>tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),</description>
    <arm_group_label>active tDCS</arm_group_label>
    <arm_group_label>sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any stage of cancer, with a confirmed treatment plan consisting of taxane-based or&#xD;
             oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy&#xD;
             with VAS score ≥ 3 that are resistant to medical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with intracranial metallic devices or with pacemakers or any other device. -&#xD;
             -W those with extensive myocardial ischemia,&#xD;
&#xD;
          -  higher brain dysfunction,&#xD;
&#xD;
          -  migraine headache,&#xD;
&#xD;
          -  brain cancer or metastasis and&#xD;
&#xD;
          -  those known to have epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shereen M Kamal, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shereen M Kamal, Associate professor</last_name>
    <phone>01006279209</phone>
    <email>sheridouh79@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assiut</city>
        <zip>11715</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shereen M Kamal, Lecturer</last_name>
      <phone>01006279209</phone>
      <email>sheridouh79@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shereen Mamdouh</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>brain stimulation</keyword>
  <keyword>chemotherapy induced peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

